Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02478879 · ClinicalTrials.gov registry record · Phase 1
A Study to Determine the Patient Preference Between Zosano Pharma Parathyroid Hormone (ZP-PTH) Patch and Forteo Pen
A Phase 1 study, sponsored by Zosano Pharma Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT02478879 is a Phase 1 study that has completed, run by Zosano Pharma Corporation. The registered enrollment target is 24 participants.
The verdict
NCT02478879, a Phase 1 study, has completed, sponsored by Zosano Pharma Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to determine which of two delivery methods of Parathyroid Hormone (PTH) is preferred by patients after 14 days of use for each.
Interventions
- DRUG FORTEO
- DRUG ZP-PTH
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2015-06 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02478879
The ClinicalTrials.gov registry entry for NCT02478879 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Zosano Pharma Corporation, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which FORTEO is the first listed.
NCT02478879 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02478879 about?
NCT02478879 is a clinical study titled "A Study to Determine the Patient Preference Between Zosano Pharma Parathyroid Hormone (ZP-PTH) Patch and Forteo Pen". The purpose of this study is to determine which of two delivery methods of Parathyroid Hormone (PTH) is preferred by patients after 14 days of use for each.
What is the current status of trial NCT02478879?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2015-06. Estimated completion is 2015-12.
What interventions are being tested in trial NCT02478879?
The interventions under investigation include: FORTEO (DRUG), ZP-PTH (DRUG).
Who is sponsoring clinical trial NCT02478879?
This trial is sponsored by Zosano Pharma Corporation, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.